$100K — $150K *
Evelo Biosciences is seeking an experienced and talented Principal Analytical Scientist (Characterization), to join our dynamic organization.
Evelo Biosciences is a fast-paced company discovering drugs based on the previously unexplored biology of the interactions between the gut and the rest of the body: gut-body network. We are developing a new class of medicines that could change the standard of care for many major diseases, providing great benefit to large numbers of patients world-wide. Evelo is advancing a portfolio of medicines, including monoclonal microbials and extracellular vesicles, which use naturally evolved pharmacology to work in the gut for effects throughout the body, providing effective, convenient, safe and cost-effective medicines. As a member of the Evelo team, you will be a vital part of helping to shape Evelo’s vision: transforming therapies through this new modality of medicines, to address the unmet needs of huge numbers of patients.
We are seeking a highly motivated, driven and collaborative Principal Analytical Scientist for the Analytical Sciences organization at Evelo Biosciences. The Principal Scientist will lead the development of state-of-the art analytical methods to support comprehensive characterization of the API and drug products. This individual will be accountable for developing the analytical tools required to identify and understand the Critical Quality Attributes for a new class of biologic medicines, which is being advanced to commercialization for the first time. The successful candidate will critically evaluate scientific data and study protocols, take part in and/or lead cross-functional teams, and drive the critical development of our understanding about the key attributes of this new class of product. This is a once-in-a-lifetime opportunity to drive a new modality, ensuring that the product characterization activities are fit-for purpose, and per regulatory requirements.
Education and Experience:
Desired Personal and Business Qualifications:
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Valid through: 11/19/2021
$150K — $200K *
5 days ago